Comparison of Biotage and competitor oligonucleotide synthesis methodologies

Synthesizing oligonucleotides often leads to the production of impurities that can be detrimental to downstream applications. These impurities are typically shorter, truncated versions of the full-length oligonucleotide. To ensure high-quality results, the solid phase synthesis and chromatographic purification processes must be carefully optimized and precisely controlled to minimize the presence of truncated side-products, leaving the oligonucleotide in a highly pure form. Biotage recognizes the need for continuous optimization of our synthesis and purification processes to ensure that our oligonucleotides are of the highest quality. This technical note compares a Biotage
oligonucleotide to the same sequence supplied by another vendor. 

Literature number: PPS701